Jul 16, 2025 | News |
The Tribal Biotechnology & Health Consortium today filed a 910-page substantive comment with the Centers for Medicare & Medicaid Services on the proposed CY 2026 Medicare Physician Fee Schedule. The filing, docketed at Regulations.gov as Comment ID...
Jun 12, 2025 | News |
The Tribal Consortium’s Authorized Tribal Agent, Clear Health Pass Holdings, joined a working session with CMS Drug Pricing and the Coverage and Analysis Group to address the Average Sales Price submission and HCPCS code record for Rampart™ DL Matrix (Q4347). The...
May 22, 2025 | News |
The Centers for Medicare & Medicaid Services convened a formal Tribal Consultative Meeting with Clear Health Pass Holdings, Authorized Tribal Agent for the Tribal Biotechnology & Health Consortium, to review the federal coverage and reimbursement framework for...
Jan 21, 2025 | News |
Clear Health Pass Holdings, LLC today completed its acquisition of exclusive worldwide commercial rights, administrative authority, and HCPCS Q-code holder responsibilities for Rampart™ DL Matrix (Q4347), the FDA-cleared advanced wound care matrix used by physicians...
Jun 24, 2024 | News |
The Tribal Consortium, represented by Clear Health Pass Holdings, joined Centers for Medicare & Medicaid Services policy leadership and Novitas Solutions — the Medicare Administrative Contractor authoring the Local Coverage Determination for skin substitute...
Jun 6, 2024 | News |
On June 6, 2024, the Tribal Biotechnology & Health Consortium — through its founding partner, Blue Lake Rancheria Economic Development Corporation — submitted formal comments to the Centers for Medicare & Medicaid Services on the Local Coverage Determination...
